Last reviewed · How we verify
Zoloft tablets
Zoloft selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Zoloft selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder.
At a glance
| Generic name | Zoloft tablets |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Zoloft (sertraline) is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing neurotransmission and improving mood regulation. The mechanism is thought to underlie its efficacy in treating depression, anxiety disorders, and related conditions.
Approved indications
- Major depressive disorder
- Obsessive-compulsive disorder
- Panic disorder
- Posttraumatic stress disorder
- Social anxiety disorder
- Premenstrual dysphoric disorder
Common side effects
- Nausea
- Diarrhea
- Headache
- Tremor
- Insomnia
- Sexual dysfunction
- Somnolence
- Dry mouth
Key clinical trials
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
- Efficacy of Statins Among Major Depressive Disorder (PHASE3)
- Cognitive Behavioral Couple Therapy for Perinatal Distress (NA)
- Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD) (NA)
- Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD (PHASE3)
- Stress & Premenstrual Symptoms Study (PHASE4)
- Allopregnanolone and Dynamic GABA-A Receptor Plasticity in Selective Serotonin Reuptake Inhibitor Responsive Premenstrual Dysphoric Disorder (PHASE4)
- Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |